1. Scrip
  2. >>R&D
  3. >>Trial Results

Amgen/AstraZeneca’s Tezspire Shows Efficacy In Broader COPD Population

Phase III Planning Under Way

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Anti-TSLP antibody Tezspire (tezepelumab) showed efficacy in a Phase IIa study versus placebo in COPD patients with lower eosinophil levels than those tested in Dupixent’s pivotal studies.

Human Respiratory System Lungs Anatomy. Man silhouette healthy lungs medicine model.
Tezspire showed greater efficacy in COPD patients with blood eosinophil counts of 150 or greater • Source: Shutterstock

Amgen, Inc. and AstraZeneca PLC still are working out the specifics of their Phase III program for Tezspire (tezepelumab) in chronic obstructive pulmonary disease (COPD), including whether enrollment will be limited to patients with specific eosinophil levels, but the companies believe newly presented Phase IIa results in COPD justify moving the anti-TSLP antibody into pivotal trials.

Key Takeaways

  • Tezspire showed greater efficacy in a Phase IIa trial in COPD in patients with high eosinophil levels than in Phase III trials of Dupixent, with efficacy in a broad range of blood eosinophil counts (BEC).

Results from the Phase IIa COURSE clinical trial in COPD were detailed on 19 and 20 May at the American...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D